Abstract |
Osteoporosis is one of the most common metabolic bone diseases among pre- and post-menopausal women. Despite numerous advances in the treatment of osteoporosis in recent years, the outcomes remain poor due to severe side effects. In this study, we investigated whether A-485, a highly selective catalytic p300/CBP inhibitor, could attenuate RANKL-induced osteoclast differentiation and explored the underlying molecular mechanisms. The protective role of A-485 in osteoporosis was verified using a mouse model of ovariectomy (OVX)-induced bone loss and micro-CT scanning. A-485 inhibited RANKL-induced osteoclast differentiation in vitro by reducing the number of tartrate-resistant acid phosphatase-positive osteoclasts without inducing significant cytotoxicity. In particular, A-485 dose-dependently disrupted F-actin ring formation and downregulated the expression of genes associated with osteoclast differentiation, such as CTSK, c-Fos, TRAF6, VATPs-d2, DC-STAMP, and NFATc1, in a time- and dose-dependent manner. Moreover, A-485 inhibited the RANKL-induced phosphorylation of MAPK pathways and attenuated OVX-induced bone loss in the mouse model while rescuing the loss of bone mineral density. Our in vitro and in vivo findings suggest for the first time that A-485 has the potential to prevent postmenopausal osteoporosis and could therefore be considered as a therapeutic molecule against osteoporosis.
|
Authors | Shicheng Huo, Xuesong Liu, Shutao Zhang, Zhuocheng Lyu, Jue Zhang, You Wang, Bin'en Nie, Bing Yue |
Journal | International immunopharmacology
(Int Immunopharmacol)
Vol. 94
Pg. 107458
(May 2021)
ISSN: 1878-1705 [Electronic] Netherlands |
PMID | 33626422
(Publication Type: Journal Article)
|
Copyright | Copyright © 2021 Elsevier B.V. All rights reserved. |
Chemical References |
- A-485 compound
- Bone Density Conservation Agents
- Heterocyclic Compounds, 4 or More Rings
- Membrane Proteins
- Pag1 protein, mouse
- Phosphoproteins
- E1A-Associated p300 Protein
- Ep300 protein, mouse
|
Topics |
- Animals
- Bone Density Conservation Agents
(pharmacology, therapeutic use)
- Bone Resorption
(drug therapy)
- Cell Differentiation
(drug effects)
- Cell Line
- E1A-Associated p300 Protein
(antagonists & inhibitors)
- Female
- Heterocyclic Compounds, 4 or More Rings
(pharmacology, therapeutic use)
- Membrane Proteins
(antagonists & inhibitors)
- Mice, Inbred C57BL
- Osteoclasts
(drug effects, physiology)
- Osteoporosis
(drug therapy)
- Ovariectomy
- Phosphoproteins
(antagonists & inhibitors)
- Rats
|